{"disease":{"id":"melanoma-of-skin","name":"melanoma of skin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT03621462","title":"Elucid Labs AIDA™ - Labelled Image Acquisition Protocol","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Elucid Labs Inc.","has_results":false},{"nct_id":"NCT06661577","title":"An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of Auckland, New Zealand","has_results":false},{"nct_id":"NCT07347392","title":"The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2900,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03313492","title":"Modifying Young Adult Skin Cancer Risk and Protective Behaviors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1746,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05602337","title":"A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"DermTech","has_results":false},{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06654999","title":"How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.","phase":"","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Skin Analytics Limited","has_results":false},{"nct_id":"NCT06152367","title":"Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"University of Chile","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"KaliVir Immunotherapeutics","has_results":false},{"nct_id":"NCT06965231","title":"Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03370861","title":"How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes","phase":"","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT07031830","title":"APA (Adapted Physical Activity) for Patients With Advanced Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT03894618","title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT04913220","title":"A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT04337931","title":"A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":45,"lead_sponsor_name":"Apexigen America, Inc.","has_results":true},{"nct_id":"NCT03093909","title":"Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06784648","title":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT01973322","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized \"Proof-of-principle\" Phase II Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT03131908","title":"Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06994208","title":"Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Ente Ospedaliero Ospedali Galliera","has_results":false},{"nct_id":"NCT06753136","title":"Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT02816021","title":"Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03420963","title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02748564","title":"Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT07428941","title":"Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.","phase":"","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"AI Labs Group S.L","has_results":false},{"nct_id":"NCT02650635","title":"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}